China’s NMPA accepted Hutchmed’s NDA for fanregratinib (HMPL‑453), an FGFR‑targeted therapy for intrahepatic cholangiocarcinoma, granting priority review based on a single‑arm phase II registration study. Separately, Innovent Biologics secured NMPA approval for Tabosun (ipilimumab N01, IBI‑310) in combination with sintilimab as neoadjuvant therapy for MSI‑high / dMMR resectable colon cancer. Both moves underscore China’s continued willingness to use expedited pathways and domestic development to expand oncology options. Companies will face post‑approval commitments, commercialization planning in China, and potential implications for global development strategies.